A US health panel has moved to ease restrictions on certain peptides, substances that have seen a surge in popularity, particularly online. The decision by the Food and Drug Administration (FDA) panel could widen access to these compounds.
Among the peptides considered, the panel specifically voted to place BPC-157 on a compounding list. These peptides have been promoted by wellness influencers, though medical professionals have urged caution regarding their use and effectiveness.
The FDA panel's backing for easier access comes amidst ongoing discussions about the safety and regulation of these controversial substances. This is a developing story and will be updated as details emerge.
